EDRF1-AS1

Across TCGA pan-cancer cohorts, EDRF1-AS1 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of EDRF1-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where EDRF1-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types EDRF1-AS1 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

BLCA, LIHC, and COAD are the cancer types where EDRF1-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in EDRF1-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	Female	All	+0.161	.013	6	view →
LIHC	All	All	+0.043	<.001	5	view →
COAD	Female	IV	+0.605	.010	3	view →
CHOL	All	All	+0.361	.014	3	view →
BRCA	All	IV	+0.365	.046	2	view →
PRAD	All	All	+0.282	<.001	2	view →
THCA	All	II,III,IV	−0.162	.035	2	view →
KIRC	All	All	+0.055	.018	2	view →
STAD	Male	II,III,IV	+0.160	.019	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

EDRF1-AS1–BLCA

Open the BLCA breakdown →